D
espite therapeutic advancements, cardiovascular disease is still the leading cause of death and a major cause of disability that affects >23 million patients worldwide, including 5.8 million people in the United States. 1 Most of the clinically approved therapeutics for the treatment of ischemic heart disease after acute myocardial infarction (MI) focus on modulating hemodynamics to reduce early mortality but do not facilitate the cardiac repair that is needed to reduce the incidence of heart failure. 2 Therefore, in recent years, cell therapy after MI has been a focus of intense research and debate. 3, 4 Different cell types, including mesenchymal stem cells, cardiac progenitor cells, cardiosphere-derived cells, embryonic stem cells, and induced pluripotent stem cells (iPSCs), have been investigated in both preclinical and clinical studies, [5] [6] [7] [8] [9] [10] [11] but overall, the studies yielded variable results, and the basic mechanisms that underlie efficacious cell therapy remain unclear. 12 It has been proposed that the transplanted cells are able to release angiogenic factors, protect cardiomyocytes from apoptotic cell death, and recruit resident cardiac stem cells that facilitate cardiac repair. 13 Recently, several studies have reported the use of cardiomyocytes derived from embryonic stem cells or from iPSCs (iPSC-CMs) in providing functional benefits after MI, although there has been no consensus about the protective mechanism induced by these differentiated cardiomyocytes.
14 Background-Human induced pluripotent stem cells (iPSCs) are attractive candidates for therapeutic use, with the potential to replace deficient cells and to improve functional recovery in injury or disease settings. Here, we test the hypothesis that human iPSC-derived cardiomyocytes (iPSC-CMs) can secrete cytokines as a molecular basis to attenuate adverse cardiac remodeling after myocardial infarction. Methods and Results-Human iPSCs were generated from skin fibroblasts and differentiated in vitro with a small moleculebased protocol. Troponin + iPSC-CMs were confirmed by immunohistochemistry, quantitative polymerase chain reaction, fluorescence-activated cell sorting, and electrophysiological measurements. Afterward, 2×10 6 iPSC-CMs derived from a cell line transduced with a vector expressing firefly luciferase and green fluorescent protein were transplanted into adult NOD/SCID mice with acute left anterior descending artery ligation. Control animals received PBS injection. Bioluminescence imaging showed limited engraftment on transplantation into ischemic myocardium. However, magnetic resonance imaging of animals transplanted with iPSC-CMs showed significant functional improvement and attenuated cardiac remodeling compared with PBS-treated control animals. To understand the underlying molecular mechanism, microfluidic single-cell profiling of harvested iPSC-CMs, laser capture microdissection of host myocardium, and in vitro ischemia stimulation were used to demonstrate that the iPSC-CMs could release significant levels of proangiogenic and antiapoptotic factors in the ischemic microenvironment. 
Conclusions-Transplantation
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In this present study, we used a model of acute myocardial injury, coupled with molecular imaging techniques, to investigate the therapeutic efficacy of iPSC-CMs. Using cardiac magnetic resonance imaging and pressure-volume loops, we demonstrated that transplanted iPSC-CMs led to improved cardiac function despite limited retention of transplanted cells. We further characterized the effects of the local cardiac microenvironment on transplanted cells at the single-cell level. Specifically, when exposed to an ischemic microenvironment, iPSC-CMs were found to have increased expression of proangiogenic genes, which in turn modulate the surrounding area to render it more favorable for tolerance of ischemic damage. This suggests the presence of molecular cross-talk, which might be responsible for the observed improvement in cardiac function after MI. Collectively, our study indicates that transplanted iPSC-CMs could be an attractive therapeutic modality for MI because they are capable of secreting prosurvival factors under harsh conditions to potentially aid recovery of the injured heart.
Methods
An extended Methods section is available in the online-only Data Supplement.
Study Design
A schematic overview of the study is summarized in Figure I in the online-only Data Supplement. Ligation of the middle left anterior descending artery (LAD) was performed in adult female NOD/SCID mice. Mice were randomized into 3 groups: (1) sham with no occlusion, (2) occlusion with 2×10 6 iPSC-CMs, and (3) occlusion with saline. The animals were injected in the peri-infarct zone with a total volume of 20 µL. Cell survival was monitored by serial optical bioluminescence imaging (BLI) using the same set of mice on days 2, 4, 7, 10, 14, 21, 28, and 35 with D-Luciferin delivered intraperitoneally. Cardiac function was assessed by magnetic resonance imaging on days 7 and 35 after MI (n=8 per group). Histological analysis was performed on hearts from randomly selected animals (n=5 per group). Transplanted cells were harvested from a subset of animals in both the LAD ligation (n=5) and sham (n=4) groups at 4 days after cell delivery by explantation of the heart followed by collagenase digestion and fluorescence-activated cell sorting-based collection of green fluorescent protein (GFP)-positive cells. RNA was harvested and used for single-cell quantitative reverse transcription-polymerase chain reaction (RT-PCR). 15, 16 Laser capture microdissection (LCM) of host myocardium proximal to transplanted cells was used to analyze the expression of proangiogenic genes after cell transplantation (n=4) as previously described. 17 Finally, in vitro experiments using iPSC-CMs under control and ischemic conditions were analyzed by fluorescence-activated cell sorting, RT-PCR, and Luminex cytokine profiling.
Culture and Maintenance of iPSCs.
Fibroblasts from a healthy human donor were used, and iPSCs were derived with lentiviral vectors carrying the Yamanaka reprogramming factors Oct4, Sox2, Nanog, and cMyc. Human iPSCs were grown to 90% confluence 18, 19 on Matrigel-coated plates (ES Qualified, BD Biosciences, San Diego, CA) using a chemically defined E8 medium as previously described. 20 Medium was changed daily, and cells were passaged every 4 days with Accutase (Global Cell Solutions).
Cardiac Differentiation
iPSCs were grown to 90% confluence and subsequently differentiated into beating cardiomyocytes with the use of a small molecule-based monolayer method 21 and as previously described. 22 Briefly, on day 0, cells were supplemented with a basal medium (RPMI 1640 medium [Invitrogen], 2% B27 supplement minus Insulin [Invitrogen] , and 1% penicillin/streptomycin), with the addition of CHIR99021, a selective inhibitor of glycogen synthase kinase 3β, which activates the canonical Wnt signaling pathway. On day 1, the medium was replaced with basal medium without CHIR99021 supplementation. On day 3, IWR-1, a Wnt antagonist, was added to basal medium for another 2 days. On day 5 and subsequently on every other day until harvest, the medium was replaced with fresh basal medium.
Electrophysiological Recordings of iPSC-CMs
To record action potentials, contracting monolayers were enzymatically dispersed into single cells and attached to 0.1% gelatin-coated glass coverslips as described previously 23 and detailed in the Methods section in the online-only Data Supplement.
Animal Surgery and Cell Transplantation
MI was induced in NOD/SCID mice (Charles River Laboratories, Wilmington, MA) by LAD ligation under 2% inhaled isoflurane anesthesia as described previously. 24 Mice were randomized into 3 groups: (1) sham with no occlusion, (2) occlusion with 2×10 6 iPSCCMs, and (3) occlusion with saline. The animals were injected in the peri-infarct zone with a total volume of 20 µL with a 29-gauge Hamilton syringe. All operations were performed by a blinded microsurgeon. Study protocols were approved by the Stanford Animal Research Committee. Animal care was provided in accordance with the Stanford University School of Medicine guidelines and policies for the use of laboratory animals.
BLI of Cell Transplantation
Serial BLI (n=8 per group) was performed on the same set of mice on the indicated days with the use of the Xenogen In Vivo Imaging System (Alameda, CA) as previously described. 25, 26 Recipient mice were anesthetized with isoflurane and were injected intraperitoneally with D-Luciferin (375 mg/kg body weight). Peak signals from a fixed region of interest were obtained, and signals were quantified (photons·s
) as previously described.
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Cardiac Magnetic Resonance Imaging
For evaluation of myocardial function, mice subjected to MI followed by injection with PBS or iPSC-CMs (n=8 per group) were randomly selected at days 7 and 35 after MI. The method and data analyses were performed as previously described 15 and as detailed in the Methods section in the online-only Data Supplement.
Invasive Pressure-Volume Loop Measurement
Animals receiving either iPSC-CMs (n=4) or PBS (n=4) after LAD ligation were assayed at day 35 after surgery. Simultaneous measurements of pressure and volume were obtained with a specialized conductance catheter (Millar Instruments, Houston, TX) as described previously 26 and detailed in the Methods section in the online-only Data Supplement.
Tissue Fixation and Immunohistochemical Analysis
Histological analysis was performed on randomly selected hearts from mice subjected to MI with PBS or iPSC-CMs (n=5 per group) as described previously. 26 After intubation, the chest was opened, and the heart was perfusion fixed for 2 minutes at 120 mm Hg with 4% paraformaldehyde (Sigma, St. Louis, MO) in PBS via left ventricular (LV) stab. Fixed hearts were immersed in 30% sucrose overnight, embedded into optimal cutting temperature compound (TissueTek), frozen, and sliced into 8-μm-thick frozen sections. Rabbit antihuman cardiac troponin T (ab45932, Abcam), mouse anti-α actinin (A7811, Sigma Aldrich), and rat anti-CD31 antibody (550274, BD Pharmingen) staining was carried out. Primary antibodies were used at dilutions of 1:200 (anti-cardiac troponin T), 1:600 (anti-α actinin), 
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Single-Cell Gene Expression Profiling of Transplanted iPSC-CMs
Transplanted cells were harvested from a subset of animals in both the LAD ligation (n=5) and sham (n=4) groups at 4 days after delivery by explantation of the heart followed by collagenase digestion and fluorescence-activated cell sorting-based collection of GFP + cells. RNA was harvested and used for single-cell quantitative RT-PCR (Fluidigm) as detailed in the Methods section in the online-only Data Supplement.
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LCM of Host Myocardium Proximal to Transplanted Cells
To analyze the expression of proangiogenic genes after cell transplantation, LCM of host myocardium surrounding transplanted cells was used (n=4), and total RNA was extracted as described previously 15 and detailed in the Methods section in the online-only Data Supplement.
In Vitro Analysis of Paracrine Function
iPSC-CMs were subjected to simulated ischemia in vitro under hypoxic conditions at 37°C for 12 hours, adapted from the method of Hamacher-Brady et al. 29 Analysis of secreted material was performed with a Luminex-based platform (Affymetrix) as published previously 24 and detailed in the Methods section in the online-only Data Supplement.
Statistical Analysis
All statistical analyses were carried out with SigmaStat 3.5 (SPSS Inc, Chicago, IL). The normality of data distribution and the homogeneity of variances were assessed by the Shapiro-Wilk test and Levene test, respectively. All values were expressed as mean±SEM. Linear regression analysis was performed to estimate the correlation between 2 variables. The differences between 2 independent groups were compared with the Student t test, and differences among ≥3 groups were tested with 1-way ANOVA followed by the Tukey post hoc test. With small sample sizes or when the normality test failed, the Mann-Whitney ranksum test was used. For data with unequal variances between groups, an unpaired t test with the Welch correction was applied. To test serial changes in BLI signal, a 1-way repeated-measures ANOVA followed by the Tukey post hoc analysis was conducted. Values of P<0.05 were considered statistically significant.
Results
Generation and Characterization of iPSCs and iPSC-CMs
A human iPSC line was generated by lentivirus-mediated transduction of Oct4, Sox2, Klf4, and c-Myc using primary human adult dermal fibroblasts obtained from a healthy patient ( Figure 1A ). The iPSC colonies revealed high gene expression levels of pluripotency markers such as Oct4, Nanog, and Sox2 as assessed by RT-PCR ( Figure 1B ) and stained positive for pluripotency markers such as Oct4, Nanog, TRA-1-60, and TRA-1-81 when assessed by immunohistochemistry ( Figure 1C ). As a definitive test for pluripotency, undifferentiated iPSCs were injected into immunocompromised NOD/ SCID mice and were found to form teratomas at 8 weeks after transplantation that contain cell derivatives of all 3 germ Next, iPSCs were differentiated to cardiomyocytes with the use of a small molecule-based protocol. 30 Cells were grown on Matrigel and started contracting spontaneously at about day 10 of differentiation. RNA sequencing of iPSC-CMs revealed an upregulation of cardiac genes and a downregulation of pluripotent genes compared with undifferentiated iPSCs, demonstrating a successful conversion of iPSCs into cardiomyocytes ( Figure 1D ). Immunostaining of iPSC-CMs also revealed a marked expression of sarcomeric proteins such as α-sarcomeric actinin and troponin T ( Figure 1E ). Overall, the differentiation efficiency was robust, with ≈90% troponin T + iPSC-CMs as assessed by flow cytometry ( Figure 1F ). Functional electrophysiological characterization of the iPSCCMs in vitro with the single-cell patch-clamp technique demonstrated different types of cardiomyocytes with node-like, atrium-like, and ventricle-like action potential morphologies ( Figure 1G ). Overall, ≈65% of the analyzed cells showed a ventricle-like morphology; ≈32%, atrium-like; and ≈3%, node-like ( Figure 1H ). Basic electrophysiological properties of the analyzed iPSC-CMs are summarized in Table I in the online-only Data Supplement.
Limited Engraftment of iPSC-CMs in the Ischemic Myocardium
We next investigated whether iPSC-CMs could survive and engraft after transplantation into ischemic myocardium. To enable in vivo tracking of cell engraftment longitudinally, the undifferentiated iPSC line was transduced with a lentiviral construct expressing firefly luciferase (Fluc) and enhanced GFP (Figure 2A Figure 2D and 2E).
Transplantation of iPSC-CMs Improves Cardiac Function After Acute MI
Despite the limited engraftment of transplanted iPSC-CMs, which has also been reported with other cell types, 31, 32 we were interested to investigate the potential therapeutic efficacy of these transplanted cells in vivo. We compared the functional recovery between mice injected with PBS and mice injected with iPSC-CMs after acute MI. With cardiac magnetic resonance imaging, LV function as assessed by ejection fraction was found to be significantly reduced in both groups at 7 days after MI with no discernible difference between control mice and iPSC-CM mice (19.2±1.8% versus 20.6±1.1%; Figure 3A and 3B). However, mice injected with iPSC-CMs had significantly improved LV function compared with PBS-treated controls when measured at 35 days after MI (24.5±1.3% versus 14.5±1.5%; P<0.05; Figure 3C ). These findings were further corroborated with the pressure-volume loop measurement at day 35, which revealed less dilation of the LV and higher contractility in mice treated with iPSC-CMs compared with control animals ( Figure 3D and 3E ).
Attenuated Cardiac Remodeling With Increased Neoangiogenesis and Reduced Apoptosis After iPSC-CM Transplantation
To better understand the preserved LV function after transplantation of iPSC-CMs in ischemic mice, we performed histological analysis of the myocardium by examining thin sections of the gross specimen via immunofluorescence microscopic examination. Histopathologic analyses of tissue samples at week 4 after LAD occlusion revealed a transmural MI in both groups ( Figure 4A) . Quantification of infarct size demonstrated significantly smaller infarct size in mice injected with iPSC-CMs compared with control mice ( Figure 4B ). Moreover, PBS-treated control mice showed a pronounced wall thinning and apical aneurysms compared with the treatment group injected with iPSC-CMs ( Figure 4C ). Microscopic examination at day 7 after MI demonstrated the presence of GFP + iPSC-CMs expressing α-sarcomeric actin and human-specific troponin T ( Figure 4D ). However, the overall frequency of GFP + iPSC-CMs was significantly decreased at day 28 (data not shown), which is consistent with the decrease in bioluminescence signals measured over this same period of time.
Immunohistochemistry analysis of the peri-infarct area with CD31 staining revealed that the area of CD31 + capillaries per 
Release of Proangiogenic and Prosurvival Factors by iPSC-CMs in Response to Ischemia In Vitro
Given that the majority of cells did not survive beyond 4 weeks after transplantation, we hypothesized that iPSC-CMs may release paracrine factors that promote angiogenesis and reduce apoptosis in the setting of ischemia, accounting for the functional benefit and attenuated cardiac remodeling that was observed. To explore this hypothesis, we investigated the angiogenic and antiapoptotic potential of iPSC-CMs by using a simulated ischemic environment assay to assess the expression of genes encoding proangiogenic factors by realtime quantitative PCR ( Figure 5A ). iPSC-CMs subjected to in vitro ischemia showed significantly increased expression of the angiogenic and antiapoptotic factors Vegf-a, Vegf-b, Ang1, Fgf-1, Egf, Il-1α, Pdgf-α, Tnf-α, Tgf-α, and Sdf-1α compared with normoxic conditions ( Figure 5B ). To confirm that iPSCCMs are also able to secrete growth factors under ischemic conditions, we used the Luminex cytokine assay to analyze the supernatant of the control and ischemic iPSC-CMs. As shown in Figure 5C , ischemia led to a significant release of proangiogenic and prosurvival genes compared with normoxic conditions, indicating that iPSC-CMs can provide a framework that could potentially support new vessel growth and protect against cell death via secretion of paracrine factors.
Increased Expression and Secretion of Proangiogenic and Prosurvival Factors After iPSC-CM Transplantation In Vivo
After demonstrating the potential of iPSC-CMs to express and secrete proangiogenic and prosurvival cytokines under ischemic conditions in vitro, we next hypothesized that transplanted cells are also able to express and secrete growth factors and cytokines in vivo, which is the driver for the neoangiogenesis and cell survival that generates cardioprotective effects. Because of the heterogeneous nature of transplanted cell populations, especially those derived from multipotent cell lines such as iPSCs and their derivatives, it is important to study the expression of genes at the single-cell level. 16 Therefore, we injected the iPSC-CMs into the peri-infarct zone of mice immediately after MI or into the same anatomic location of control mice with noninfarct sham surgery (control). Four days after cell transplantation, hearts were explanted and digested to purify single GFP + iPSC-CMs transplanted into ischemic versus nonischemic regions. Individually fluorescence-activated cell sorting-isolated iPSC-CMs were analyzed for expression of genes related to angiogenesis and apoptosis with the use of the microfluidic single-cell PCR platform ( Figure 6A and 6B) . About 90% of these isolated individual iPSC-CMs retained troponin T + expression (data not shown). A number of genes were significantly expressed in the iPSC-CMs injected into the border zone compared with iPSC-CMs injected into nonischemic region, including Hif-1α, Vegf-α, Vegf-b, Ang1, Hgf, Fgf-2, Egf, Tgf-α, Tnf-α, and Sdf-1α ( Figure 6C ). Having shown that iPSC-CMs display a different gene expression profile on exposure to ischemic stress, we sought to further confirm that transplanted cells are able to express and secrete growth factors and cytokines. We harvested the host myocardium surrounding the transplanted cells by LCM and performed quantitative real-time RT-PCR Figure 5 . Differential expression of proangiogenic and prosurvival factors by induced pluripotent stem cell-cardiomyocyte (iPSCCMs) in response to ischemia in vitro. A, Schematic diagram depicting iPSC-CMs under control and ischemic conditions. Cells were subjected to reverse transcription-polymerase chain reaction (RT-PCR), and supernatant was profiled with the Luminex cytokine assay. B, Gene expression analysis revealed that iPSC-CMs under ischemic conditions significantly increased the expression of several proangiogenic and antiapoptotic factors compared with normoxic condition (n=4; *P<0.05 by unpaired t test with the Welch correction). C, Luminex cytokine array of iPSC-CMs under control and ischemic conditions showed significant release of cytokines in the supernatant of ischemic iPSC-CMs compared with control supernatant (n=4; *P<0.05 by the Mann-Whitney rank-sum test). CSF-3 indicates colony-stimulating factor-3; FGF-B, fibroblast growth factor-B; HGF, hepatocyte growth factor; ICAM-1, intercellular adhesion molecule-1; IL-1α, interleukin-α; PDGF, platelet-derived growth factor; SCF, stem cell factor; TFG-α, transforming growth factor-α; TNF-α, tumor necrosis factor-α; and VEGF, vascular endothelial growth factor. 
Ong et al Paracrine Activation of Human iPSC-CMs 769
of proangiogenic and prosurvival genes at day 4 after MI. The remote nonischemic tissue of the same heart was used as internal controls. Vegf-α, Fgf-2, Ang1, and Hgf genes showed significantly higher levels in the peri-infarct area collected from mice treated with transplanted cells compared with those without cell injection ( Figure 6D ). Importantly, we found that injection of concentrated conditioned medium harvested from iPSC-CMs into acutely infarcted mice hearts resulted in a modest but significant reduction in infarct size compared with cell-free control conditioned medium, although there was no difference between normoxic and hypoxic conditioned medium ( Figure V in the online-only Data Supplement). Taken together, these results corroborated our in vitro findings suggesting that iPSC-CMs are capable of expressing and secreting a variety of proangiogenic and prosurvival factors under ischemic conditions, resulting in functional improvement and attenuated cardiac remodeling.
Discussion
A variety of different stem cell types have been investigated for their ability to repair the infarcted heart in both preclinical studies and human clinical trials. 12 The use of iPSC technology has added a cell source that may have potential clinical applications in this field, and one of its derivatives (ie, iPSCderived retinal pigment cells) is already in clinical trial in Japan. 33 The major findings of this study are summarized here: (1) Transplantation of iPSC-CMs into the acute MI mouse model resulted in limited engraftment; (2) despite limited engraftment, transplanted iPSC-CMs promoted cardioprotection and attenuated cardiac remodeling compared with PBStreated control animals; and (3) mechanistically, iPSC-CMs at the single-cell level could increase expression of proangiogenic and antiapoptotic cytokines after ischemia in vitro and in vivo, which was associated with increased neovascularization and reduced apoptosis. In our study, most of the transplanted iPSC-CMs failed to survive long term in the infarcted heart, highlighting one of the major bottlenecks of cell-based therapy. Precluding the possibility of immune rejection as immunodeficient mice were used in this study, the transplanted iPSC-CMs would still need to survive the initial highly inflammatory response associated with the acute infarct, integrate into the host myocardium to receive blood supply, and ultimately couple with residual host cardiomyocytes to contract synchronously, which is challenging considering the stark difference in heartbeats between human iPSC-CMs and murine hearts. Multifactorial strategies for cardiac repair are currently being developed to enhance the survival of transplanted cells, including combining gene and cell therapy, 25 bioengineering methods such as 3-dimensional materials, 34 and genetic modification of cells, 35 which will, we hope, overcome the issue of poor survival.
Despite the limited engraftment of iPSC-CMs, it was encouraging to observe preserved cardiac function in mice receiving iPSC-CMs compared with PBS at up to 5 weeks after MI. The observation that actual cell engraftment is not needed to promote functional improvement points toward the possibility of paracrine factors secreted by iPSC-CMs as the driving force behind the beneficial effects. This is consistent with our findings of increased vascularity and reduced apoptosis in iPSC-CM-treated mice compared with control mice, which may be sufficient to explain the transient protection observed here and is in accordance with the paracrine concept that has been robustly demonstrated in other cell types such as mesenchymal stem cells. [36] [37] [38] The majority of studies to date have looked at secretion of paracrine factors in vitro without investigating the expression of these factors in an in vivo setting. Likewise, other groups have investigated the expression profile of paracrine factors after injection, but only at a total myocardial expression level, not necessarily examining the expression profile of the cells of interest. 39 Given the heterogeneous nature of iPSC-CMs (which are influenced by limitations in reprogramming, differentiation efficiency, and type of iPSC-CMs, ie, ventricle, atrium-, or node-like), we used a novel microfluidic platform to examine the gene expression profile of injected iPSC-CMs in vivo at the single-cell level. We have previously validated this platform to investigate the manner by which porcine iPSCderived endothelial cells provided cardioprotection against MI. 15 In this study, we have extended the use of this platform to study the paracrine effects of human iPSC-CMs in vitro and in vivo for the first time, including the cross-talk effects afforded by paracrine molecules on the surrounding myocardium by LCM. An initial in vitro comprehensive analysis of iPSC-CMs revealed that these cells had higher expression and secreted paracrine factors when exposed to simulated ischemic conditions compared with normoxia. We further confirmed these findings in vivo by recovering individual transplanted iPSC-CMs from sham or infarcted mice, which revealed that iPSC-CMs in an ischemic heart had a higher expression of paracrine factors. Notably, these released factors are able to modulate host myocardium, leading to a change in the milieu as measured by LCM analysis of myocardial tissue surrounding the site of engraftment. In-depth molecular analysis in the future would be beneficial to unravel the secretome of these iPSC-CMs, which could be used to further enhance paracrine signals as a new approach for eliciting cardioprotection.
Conclusions
We have shown that, despite poor survival of iPSC-CMs in a murine model of MI, preservation of cardiac function was still observed and associated with increased vascularity and reduced apoptosis. Although engraftment was limited, transplanted iPSC-CMs in an ischemic microenvironment promote proangiogenic and antiapoptotic paracrine factors, which can then modulate the ischemic heart to render it more resistant (ie, resulting in increased vasculogenesis and decreased apoptosis) and to form a basis of molecular cross-talk, a concept that is well established in cancer studies but has yet to be fully explored in cardiac regenerative mechanisms. In the future, further development of methods to improve survival of these iPSC-CMs would likely enhance their protective effects.
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SUPPLEMENTAL MATERIAL Microfluidic Single Cell Analysis of Transplanted Human Induced Pluripotent Stem CellDerived Cardiomyocytes Following Acute Myocardial Infarction
Sang-Ging Ong, PhD were used. Cardiomyocyte stainings were done as previously described 1 . Pictures were taken with 10x, 20x, and 40x plan apochromat, and 63x plan apochromat (oil) objectives using a confocal microscope (Carl Zeiss, LSM 510 Meta, Göttingen, Germany) and ZEN software (Carl Zeiss).
Electrophysiological Recordings of iPSC-CMs. Single beating cardiomyocytes were subjected to whole-cell patch-clamp at 36-37°C using an EPC-10 patch-clamp amplifier (HEKA, 3 Lambrecht, Germany) attached to a RC-26C recording chamber (Warner) and mounted on the stage of an inverted microscope (Nikon, Tokyo, Japan) as previously described 2 . Data were acquired using PatchMaster software (HEKA, Germany) and digitized at 1.0 kHz. Current-clamp recordings were conducted in Tyrode's solution.
Cardiac Magnetic Resonance Imaging (MRI).
For evaluation of myocardial function, mice subjected to MI followed by injection with PBS or iPSC-CMs (n=8 per group) were randomly selected at day 7 and day 35 post-MI. The imaging protocol as well as data analyses were performed as previously described 3 . Briefly, imaging was performed using a Signa 3.0T Excite HD scanner (GE Healthcare Systems, Milwaukee, Wisconsin) with a Mayo Clinic T/R MRI coil (Mayo Clinic Medical Devices, Rochester, Minnesota). Mice were anesthetized with 1.5% isoflurane with oxygen (1 ml/min) and placed in the prone position for imaging. During the scan, physiologic parameters such as heart rate, respiratory rate, and body temperature were monitored RNA Sequencing. RNA was isolated using miRNeasy kit (Qiagen) according to manufacturer's instructions followed by DNAse treatment using RNase-free DNase kit (Qiagen). In brief, 100 ng of total RNA was converted to cDNA and amplified using NuGen V2 RNA-seq kit (NuGen, San Carlos, CA). Sonication of cDNA was performed to produce an average fragment size of 280 bps and Illumina sequencing adapters were ligated to 500 ng of cDNA using NEBNext® mRNA Library Prep Reagent Set (New England Biolabs, Ipswich, MA). PCR was performed on the adapter ligated cDNA using the following conditions (denaturation 98°C for 30 seconds, following 12 cycles of denaturation 98°C for 10 seconds, annealing 65°C for 30 seconds, and extension 72°C for 30 seconds, ending with an extension at 72°C for 5 min). Libraries were submitted to the Stanford Stem Cell Institute Genome Center for sequencing using Illumina's HiSeq2000 platform using paired in reads at an average length of 100 bps (2x100).
In Vitro Analysis of Paracrine Function. Supernatants from iPSC-CMs (n=4/group) were collected and centrifuged at 10,000 g for 10 min at 4°C and stored at -80°C. RNA was extracted from 1x10 6 cells (n=4/group) via an RNeasy Mini Kit (Qiagen) and quantitative RT-PCR was carried out as described above. Analysis of secreted material was performed using a Luminexbased platform (Affymetrix) as previously described 5 . Briefly, bead-conjugated antibodies in a 96-well plate format were used to capture individual cytokines. Plates were incubated at room temperature for 2 hr and at 4°C for 18 hr, washed and subsequently incubated with a biotin- Specific green fluorescent tissues, as well as normal cardiac tissues without green fluorescence, were independently dissected out by applying Leica LCM Systems (MicroDissect GmbH). The dissected tissues were placed on the caps of microcentrifuge tubes with 5 ul lysis enhanced 8 buffer. After dissection, tissues were collected by centrifugation at 8,000 g for 5 min. Total RNA extraction and reverse transcription of these samples were performed using a commercial 1-step kit (Invitrogen) (n=4-6 mice per group).
In Vivo Experiments with Conditioned Medium of iPSC-CMs. Conditioned medium (CM) was generated as follows: 2x10 6 iPSC-CMs were cultured in routine maintenance medium and incubated in either normoxia or hypoxia for 12 hr. The medium was then collected, filtered through a 0.22 µM filter to clear cell debris, followed by a 50-fold concentration using a Ultracel-100K filter (Amicon, Millipore, USA) according to the manufacturer's protocol.
Control CM was generated in the same way except there were no cells in the plate.
A total volume of 80 µl of CM (control CM, normoxic CM, or hypoxic CM; n=6/group) was injected in three different sites at the infarct border zone 15 min after ligation. The mice in each group (n=6/group) were also given an additional intraperitoneal injection of 80 µl of CM on days 2 and 4 after infarction 8 . Infarct size was measured as described above on day 28 post-LAD ligation. 
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